Polycystic ovary syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review synthesizing pathophysiology, diagnostic criteria, and management of PCOS without systematic review methodology.
PubMed 35934017 · doi:10.1016/S2213-8587(22)00163-2
What was done
This is a narrative review summarizing current evidence on the pathophysiology, diagnosis, clinical phenotypes across the lifespan, and management strategies for polycystic ovary syndrome (PCOS), based on international evidence-based guidelines.
What was found
The abstract reports that PCOS affects 5–18% of women. Diagnosis under the 2003 Rotterdam criteria requires two of three features: hyperandrogenism, irregular cycles, and polycystic ovarian morphology (adolescents require both hyperandrogenism and irregular cycles, excluding ovarian morphology). Four phenotypes are recognized. Management centers on lifestyle optimization (diet, exercise) combined with pharmacological options: metformin for insulin resistance, combined oral contraceptives for cycle regulation and hyperandrogenism, and anti-androgens for refractory cases. No comparative statistical effect sizes or trial numbers are provided in the abstract.
Why it matters
It provides a consolidated framework for diagnosing PCOS across different age groups and highlights the multi-organ, reproductive, metabolic, and psychological dimensions of the disorder.
Limits
The abstract describes a broad narrative review rather than a systematic review or meta-analysis; it does not detail search methods, study quality assessments, or specific quantitative trial outcome data.
Cited by
- supports High testosterone levels in blood are not required to diagnose PCOS if clinical symptoms of hyperandrogenism are present.